Orchid Pharma sees pricing recovery, targets 12% EBITDA margin for FY27
Worst of cephalosporin pricing cycle may be behind, but execution on new platforms remains key.
What management said
- Q4 revenue stable at ₹238 cr, EBITDA margins recovering to ₹42.3 cr
- Merger with Dhanuka Labs expected to add 1-2% EBITDA margin via cost cuts
- Exblisset commercialisation gaining traction; Q1 European sales 4x QoQ
- Targeting 5-6 sterile US launches with $1.2 bn addressable market
- 7-ACA project on track for CY27 commissioning with 75% in-house consumption
The brief
Orchid Pharma's Q4 FY26 standalone revenue was stable at ₹238 cr YoY, with EBITDA at ₹42.3 cr vs ₹40 cr last year, signalling early recovery from a difficult pricing cycle. Full-year revenue fell to ₹811 cr (FY25: ₹922 cr) and EBITDA to ₹101 cr (FY25: ₹155 cr) due to inventory write-downs and price erosion. Gross margins recovered in Q4 as the worst of the cycle appears over. Management targets 12% EBITDA margin for the base business in FY27 and 10-15% revenue growth. The Dhanuka Labs merger is expected to add 1-2% EBITDA margin through removal of duplicate functions and compliance costs. Exblisset (Enmetazobactam) saw Q1 European sales quadruple quarter-on-quarter; lifetime sales potential remains $1-2 bn. The 7-ACA project is on track for CY27 commissioning, with 75% output consumed in-house. Orchid plans to invest in sterile fill-finish for the US, targeting 5-6 products with a $1.2 bn addressable market. The verdict: recovery is underway, but execution on multiple new platforms will determine long-term value.
In their words
“It does appear that the worst phase of the pricing cycle may now be behind us.”— Manish Dhanuka — Managing Director
“We still maintain the lifetime sales would be between 1 to 2 billion dollars overall during the life of the patent.”— Manish Dhanuka — Managing Director
“We remain committed to disciplined execution, prudent capital allocation, strengthening competitiveness and creating sustainable long term value.”— Manish Dhanuka — Managing Director
Summarised from the Orchid Pharma Ltd Q4 2026 earnings-call transcript. View transcript.